Pregnant women and the extremely obese are among those at high risk for complications from the flu – including death – and should be tested and begin antiviral treatment promptly.
Pregnant women and the extremely obese are among those at high risk for complications from the flu – including death – and should be tested and begin antiviral treatment promptly.
IDSA and HIVMA wrote to the U.S. Secretary for Health and Human Services Alex Azar, II to express concerns regarding the negative impact the review of fetal tissue research alternatives is having on HIV and infectious diseases research studies planned or underway.
People newly diagnosed with cancer, particularly blood cancers, and those on chemotherapy have a greater risk of developing shingles, a new JID study finds.
New report documents a steep climb in measles cases with severe outbreaks worldwide linked to vaccine coverage gaps indicates stalled momentum in efforts to control a preventable and deadly disease.
Findings in the fourth federal National Climate Assessment highlight immediate threats and urgent challenges the incoming Congress must take on to confront climate change and its impacts on public health.
The Journal of Infection Control and Hospital Epidemiology estimates about 162,044 people die annually from multi-drug resistant infections in the US, stressing the immediate need for strengthened research and efforts.
The Senate's approval reauthorizing PEPFAR acknowledges the program's role in reversing the trajectory of the AIDS pandemic and boosting responses against ID worldwide.
Outbreaks of norovirus in health care settings and those caused by a particular genotype of the virus are more likely to make people seriously ill, according to a new analysis.
Before patients receive intravenous (IV) antimicrobial infusion therapy outside of the hospital – whether at home, a doctor’s office or a skilled nursing facility – an infectious diseases (ID) specialist should review the order to ensure the most appropriate treatment, suggest updated guidelines released by the Infectious Diseases Society of America (IDSA).
News of continued cutbacks at one of what is already a limited number of companies conducting antibiotic research and development threatens access to a critical medicine and further validates a critical need for government-led incentives that both reward and support work towards a robust, renewable antibiotic supply.
Data showing a tripling of hepatitis C cases across America during the last decade highlight urgent and multi-faceted public health needs for expanded access to prevention.
Infectious Diseases Society of America is asking the U.S. Department of Health and Human Services to strengthen its leadership of efforts through the partnership.